How Has the Arthritic Therapeutic Market Size Evolved in Recent Years?
The arthritic therapeutic market has seen considerable growth due to a variety of factors.
• In recent years, there has been significant growth in the size of the arthritic therapeutic market. The projected growth is from $68.1 billion in 2024 to $72.44 billion in 2025, with a compound annual growth rate (CAGR) of 6.4%.
This notable expansion in the historic period is due to factors such as the rise in diagnosed patient numbers, enhanced awareness of symptoms, higher prevalence of obesity, improvement in diagnostic capabilities, and better treatment outcomes.
What are the Market Size and Expected Growth Rates for the Arthritic Therapeutic Market?
The arthritic therapeutic market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, significant expansion is anticipated in the arthritic therapeutic market. By 2029, its size is projected to reach $91.72 billion with a compound annual growth rate (CAGR) of 6.1%.
The growth predicted for this period is due to enhancements in healthcare infrastructure, governmental initiatives, supportive legislations, personalized medicine emphasis, and a shift toward patient-focused healthcare methodologies. During this forecast period, main trends will comprise a focus on biosimilars, a shift towards biologics, improved biosimilar availability, a preference for parenteral delivery, and the expansion of online pharmacies.
What Are The Key Drivers Fueling Growth In The Arthritic Therapeutic Market?
The escalating cases of arthritis are projected to fuel the expansion of the arthritic therapeutic market in the future. Arthritis implies over 100 conditions, primarily characterized by joint pain and inflammation. The aging population, heightened obesity rates, and lifestyle-related factors causing joint stress and inflammation are contributing to the rising prevalence of arthritis. Treatments for arthritis help assuage symptoms, cut down inflammation, and optimize joint function, thereby improving the overall life quality for those suffering. For instance, a report in June 2024 by the Australian Institute of Health and Welfare, a governmental organization based in Australia, revealed that around 514,000 individuals (accounting to 2.0% of the population) were diagnosed with rheumatoid arthritis in 2022. Rheumatoid arthritis constituted 2.0% of the overall disease burden and 16% of the total musculoskeletal conditions in 2023. Thus, the escalating cases of arthritis are spurring the expansion of the arthritic therapeutic market.
What Are The Key Segments Within The Global Arthritic Therapeutic Market?
The arthritic therapeuticmarket covered in this report is segmented –
1) By Drug Class: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Xanthine Oxidase Inhibitors, Other Drug Classes
2) By Route Of Administration: Oral, Parenteral, Topical
3) By Type: Psoriatic Arthritis, Rheumatoid Arthritis, Osteoarthritis, Gout, Other Types
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Tumor Necrosis Factor (TNF) Inhibitors: Adalimumab, Etanercept, Infliximab, Certolizumab Pegol, Golimumab
2) By Interleukin Inhibitors: Interleukin-6 (IL-6) Inhibitors, Interleukin-1 (IL-) Inhibitors, Interleukin-17 (IL-17) Inhibitors, Interleukin-23 (IL-23) Inhibitors
3) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Naproxen, Diclofenac, Celecoxib, Meloxicam
4) By Corticosteroids: Prednisone, Methylprednisolone, Hydrocortisone, Dexamethasone
5) By Xanthine Oxidase Inhibitors: Allopurinol, Febuxostat
6) By Other Drug Classes: Disease-Modifying Antirheumatic Drugs (DMARDs), Janus Kinase (JAK) Inhibitors, Biologic DMARDs, Topical Analgesics, Opioid Pain Medications
Pre-Book The Arthritic Therapeutic Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Arthritic Therapeutic Market?
Leading businesses in the arthritis therapeutic market are striving to create new solutions such as biosimilar monoclonal antibody-based therapies, in order to improve treatment results and minimize costs. These therapies are formulated to imitate the effectiveness of original monoclonal antibodies, consequently providing comparable therapeutic advantages at possibly lesser expenses. For example, in May 2024, Bio-Thera Solutions Ltd., a biopharmaceutical firm based in China, introduced TOFIDENCE, a biosimilar monoclonal antibody formulation modelled on ACTEMRA. TOFIDENCE (tocilizumab-bavi), a biosimilar of the ACTEMRA reference drug, has been approved for the treatment of moderate to severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.
Who Are the Key Players In The Arthritic Therapeutic Market?
Major companies operating in the arthritic therapeutic market are:
• Pfizer Inc.
• Johnson & Johnson
• Hoffmann-La Roche Ltd
• Merck & Co Inc.
• AbbVie Inc.
• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca Pharma AB
• GlaxoSmithKline plc
• Eli Lilly and Company
• Amgen Inc.
• Gilead Sciences Inc.
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Biogen Inc.
• Vertex Pharmaceuticals Incorporated
• Zimmer Biomet Holdings Inc.
• UCB Pharma S.A.Incyte Corporation
• Celltrion Inc.
• Mallinckrodt Pharmaceuticals
• Genentech Inc.
• Anika Therapeutics Inc.
• Medac GmbH
What Are The Regional Insights Into The Arthritic Therapeutic Market?
North America was the largest region in the arthritic therapeutic market in 2024. The regions covered in the arthritic therapeutic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
